ClearPlasma is an innovative medical device that enhances coagulation properties...
ClearPlasma is an innovative medical device that enhances coagulation properties for improved treatment of excessive bleeding.
Each year, almost 2 million people die from haemorrhaging, or blood loss. Massive blood loss can occur upon: Trauma, Surgery, Childbirth, Disseminated Intravascular Coagulation (DIC), Gastrointestinal Bleeding, etc. In all of thes...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ClearPlasma
An innovative filtration system to improve the coagulation p...
2M€
Cerrado
Smart Clot
SmartClot Personalized platform for the combined evaluation...
71K€
Cerrado
ACOUPLASMA
Market maturation of a blood plasma separation module enabli...
71K€
Cerrado
ThromboSLE
Accurate assessment of thrombosis risk in systemic lupus ery...
71K€
Cerrado
plasmaCare
A small portable cold plasma device for the treatment of ch...
71K€
Cerrado
Duración del proyecto: 3 meses
Fecha Inicio: 2019-11-26
Fecha Fin: 2020-02-29
Líder del proyecto
PLASFREE LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Each year, almost 2 million people die from haemorrhaging, or blood loss. Massive blood loss can occur upon: Trauma, Surgery, Childbirth, Disseminated Intravascular Coagulation (DIC), Gastrointestinal Bleeding, etc. In all of these cases, there is an urgent need for efficient plasma transfusion to halt the bleeding. However, recent studies have shown that regular plasma fails to stop massive bleeding, while other treatments show low efficacy and increased mortality risk.
ClearPlasma is an innovative filtration system that modifies human plasma to improve the treatment of massive bleeding and bleeding disorders. By extracting plasminogen, an important protein responsible for dissolving blood clots, ClearPlasma enhances coagulation and favours haemostasis, thus reducing bleeding of 55%. This translates into the opportunity to reduce up to 45% the units of plasma needed during transfusion, hence reducing treatment costs. ClearPlasma is a disposable filter that can be incorporated in current Apheresis systems thus not affecting common clinical practices. ClearPlasma addresses the Global Blood Transfusion Diagnostics Market, which was valued at approximately € 3.2bn in 2017, and is expected to reach around € 4.7bn by 2024, growing at a CAGR of 6.2% between 2018 and 2024.
The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of ClearPlasma and its market uptake.